MedPath

Defining Endpoints in Becker Muscular Dystrophy

Recruiting
Conditions
Muscular Dystrophy in Children
Muscular Dystrophies
Becker Muscular Dystrophy
Muscular Dystrophy, Becker
Registration Number
NCT05257473
Lead Sponsor
Virginia Commonwealth University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
80
Inclusion Criteria

Inclusion Criteria:<br><br>For ages 6-12<br><br> 1. Clinically affected (defined as weakness on bedside evaluation in a pattern<br> consistent with BMD)<br><br> 2. Genetic confirmation of an in-frame dystrophin mutation<br><br> 3. Ambulatory<br><br> 4. Willing and able to give informed consent and follow all procedures and requirements<br><br>For ages 13 and older<br><br> 1. Clinically affected (defined as weakness on bedside evaluation in a pattern<br> consistent with BMD)<br><br> 2. Genetic confirmation of a dystrophin mutation<br><br> 3. Willing and able to give informed consent and follow all procedures and requirements<br><br>For participants in the MRI substudy:<br><br> 1. Ambulatory, defined as able to walk 10 meters without assistive devices (orthotics<br> allowed)<br><br>Exclusion Criteria:<br><br>For ages 6-12<br><br> 1. Out of frame dystrophin mutation<br><br> 2. Use of chronic corticosteroids at baseline, defined as greater than 6 months of<br> chronic use, will be limited to 20% of the overall population<br><br> 3. Non-ambulatory, defined as the inability to walk 10 meters without assistive device<br> (excluding orthotics)<br><br> 4. >16 hours of ventilatory support<br><br> 5. Any other illness that would interfere with the ability to undergo safe testing or<br> would interfere with interpretation of the results in the opinion of the site<br> investigator.<br><br> 6. Under the age of 6 at time of enrollment<br><br> 7. For MR Cohort: Have contraindications to MRI or MRS (e.g., non-MR compatible<br> implanted medical devices or severe claustrophobia)<br><br>For ages 13 and older<br><br> 1. Loss of ambulation prior to age 16<br><br> 2. Use of chronic corticosteroids, defined as greater than 6 months of chronic use,<br> will be limited to 20% of the overall population<br><br> 3. Less than 30% of the overall population will be non-ambulatory, defined as the<br> inability to walk 10 meters without assistive device (excluding orthotics)<br><br> 4. >16 hours of ventilatory support<br><br> 5. Subjects aged 13-16 only: time to rise >10 seconds<br><br> 6. For MR Cohort: Have contraindications to MRI or MRS (e.g., non-MR compatible<br> implanted medical devices or severe claustrophobia)

Exclusion Criteria

Not provided

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess the natural history of measures of muscle function in BMD;4-Stair Climb;100-Meter Timed Test;PERFORMANCE OF UPPER LIMB 2.0 (PUL);HAND HELD DYNAMOMETRY (HHD) AND GRIP;TIMED UP-AND-GO (TUG);Measures of Pulmonary Function (Seated and supine FVC);Measures of Pulmonary Function (MEP and MIP);Measures of Pulmonary Function (other);Measure of ejection fraction (ECHO);Measure of systolic and diastolic function (ECHO)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath